Select a section from the left sidebar
16-epi-scalarolbutenolide
- Family: Animalia - Thorectidae
- Kingdom: Animalia
-
Class: Terpenoid
- Subclass: Scalarane-Type Sesterterpene
Canonical Smiles | CC(=O)O[C@H]1C[C@@H]2[C@]([C@@H]3C1=CC(=O)O3)(C)[C@H](O)C[C@H]1[C@@]2(C)CC[C@@H]2[C@]1(C)CCCC2(C)C |
---|---|
InChI | InChI=1S/C27H40O5/c1-15(28)31-17-13-20-26(5)11-8-18-24(2,3)9-7-10-25(18,4)19(26)14-21(29)27(20,6)23-16(17)12-22(30)32-23/h12,17-21,23,29H,7-11,13-14H2,1-6H3/t17-,18-,19+,20-,21+,23-,25-,26+,27+/m0/s1 |
InChIKey | NUXDYAGOJZSDBF-ZWRXBZFVSA-N |
Formula | C27H40O5 |
HBA | 5 |
HBD | 1 |
MW | 444.61 |
Rotatable Bonds | 1 |
TPSA | 72.83 |
LogP | 4.81 |
Number Rings | 5 |
Number Aromatic Rings | 0 |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Fraction CSP3 | 0.85 |
Exact Mass | 444.29 |
Number of Lipinski Rule Violations | 0 |
# | Species | Family | Kingdom | NCBI Taxonomy ID |
---|---|---|---|---|
1 | Hyrtios erecta | Thorectidae | Animalia | 279628 |
Showing of synonyms
16-epi-scalarolbutenolide
((4S,5aS,5bR,7aS,11aS,11bR,13R,13aR)-13-hydroxy-5b,8,8,11a,13a-pentamethyl-4,5,5a,6,7,7a,9,10,11,11b,12,13-dodecahydrophenanthro(1,2-g)(1)benzofuran-4-yl) acetate
((4S,5aS,5bR,7aS,11aS,11bR,13R,13aR,13bS)-13-hydroxy-5b,8,8,11a,13a-pentamethyl-2-oxo-5,5a,6,7,7a,9,10,11,11b,12,13,13b-dodecahydro-4H-phenanthro(1,2-g)(1)benzofuran-4-yl) acetate
[(4S,5aS,5bR,7aS,11aS,11bR,13R,13aR)-13-hydroxy-5b,8,8,11a,13a-pentamethyl-4,5,5a,6,7,7a,9,10,11,11b,12,13-dodecahydrophenanthro[1,2-g][1]benzofuran-4-yl] acetate
[(4S,5aS,5bR,7aS,11aS,11bR,13R,13aR,13bS)-13-hydroxy-5b,8,8,11a,13a-pentamethyl-2-oxo-5,5a,6,7,7a,9,10,11,11b,12,13,13b-dodecahydro-4H-phenanthro[1,2-g][1]benzofuran-4-yl] acetate
CHEMBL476919
No compound-protein relationship available.
SMILES: C1C(=O)OC(C=12)C3C(CC2)C4C(CC3)C5C(CC4)CCCC5
Level: 0
Mol. Weight: 444.61 g/mol
Antimycobacterial
Absorption
- Caco-2 (logPapp)
- -4.76
- Human Oral Bioavailability 20%
- Bioavailable
- Human Intestinal Absorption
- Absorbed
- Madin-Darby Canine Kidney
- -4.68
- Human Oral Bioavailability 50%
- Bioavailable
- P-Glycoprotein Inhibitor
- Non-Inhibitor
- P-Glycoprotein Substrate
- Non-Substrate
- Skin Permeability
- -2.71
Distribution
- Blood-Brain Barrier (CNS)
- -
- Blood-Brain Barrier
- Penetrable
- Fraction Unbound (Human)
- 1.22
- Plasma Protein Binding
- 77.37
- Steady State Volume of Distribution
- -
Metabolism
- Breast Cancer Resistance Protein
- Non-Inhibitor
- CYP 1A2 Inhibitor
- Non-Inhibitor
- CYP 1A2 Substrate
- Non-Substrate
- CYP 2C19 Inhibitor
- Non-Inhibitor
- CYP 2C19 Substrate
- Non-Substrate
- CYP 2C9 Inhibitor
- Inhibitor
- CYP 2C9 Substrate
- Non-Substrate
- CYP 2D6 Inhibitor
- Non-Inhibitor
- CYP 2D6 Substrate
- Non-Substrate
- CYP 3A4 Inhibitor
- Non-Inhibitor
- CYP 3A4 Substrate
- Substrate
- OATP1B1
- Non-Inhibitor
- OATP1B3
- Non-Inhibitor
Excretion
- Clearance
- 11.16
- Organic Cation Transporter 2
- Non-Inhibitor
- Half-Life of Drug
- -
Toxicity
- AMES Mutagenesis
- Safe
- Avian
- Safe
- Bee
- Toxic
- Bioconcentration Factor
- 0.03
- Biodegradation
- Safe
- Carcinogenesis
- Safe
- Crustacean
- Safe
- Liver Injury I (DILI)
- Safe
- Eye Corrosion
- Safe
- Eye Irritation
- Safe
- Maximum Tolerated Dose
- -0.01
- Liver Injury II
- Toxic
- hERG Blockers
- Toxic
- Daphnia Maga
- 6.02
- Micronucleos
- Safe
- NR-AhR
- Safe
- NR-AR
- Toxic
- NR-AR-LBD
- Safe
- NR-Aromatase
- Safe
- NR-ER
- Safe
- NR-ER-LBD
- Safe
- NR-GR
- Toxic
- NR-PPAR-gamma
- Safe
- NR-TR
- Safe
- T. Pyriformis
- -68.21
- Rat (Acute)
- 2.76
- Rat (Chronic Oral)
- 1.6
- Fathead Minnow
- 3.92
- Respiratory Disease
- Safe
- Skin Sensitisation
- Toxic
- SR-ARE
- Safe
- SR-ATAD5
- Safe
- SR-HSE
- Safe
- SR-MMP
- Safe
- SR-p53
- Safe
General Properties
- Boiling Point
- 477.56
- Hydration Free Energy
- -2.83
- Log(D) at pH=7.4
- 4.48
- Log(P)
- 4.37
- Log S
- -5.39
- Log(Vapor Pressure)
- -8.32
- Melting Point
- 211.1
- pKa Acid
- 9.07
- pKa Basic
- 5.86
No predicted protein targets found for this compound.